Yahoo Finance1 天
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables ...
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
BOSTON & MONTREAL, October 22, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic ...
Business Wire1 个月
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of ...
Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and ...
Stockhouse12 天
enGene Announces $60 Million Private Placement Financing
Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of ...
Financial Post12 天
enGene Announces $60 Million Private Placement Financing
Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of ...
Morningstar16 天
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as ...
He has been central to the discovery and development of the Company’s novel and proprietary Dually Derivatized Oligochitosan (DDX) platform and in the creation of detalimogene. He has co ...
Financial Post16 天
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as ...
Dr. Cheung is a co-founder of enGene and has served in various capacities since the Company’s inception. He has been central to the discovery and development of the Company’s novel and proprietary ...